The global pharmaceutical packaging market trends size is projected to reach USD 142.59 billion by 2027, exhibiting a CAGR of 6.0% during the forecast period.
Rising Prevalence of Multiple Chronic Conditions to Augment Market Growth
Multiple chronic conditions (MCC), as the name suggests, are essentially several lifelong disorders that befall a person simultaneously or in close frequency to one another. According to the World Economic Forum (WEF), approximately 33% of the world's population suffers from MCC such as a combination of cardiovascular disease with stroke. Furthermore, the WEF postulates that such conditions typically entail more medications, with each new chronic condition adding 8 new prescriptions among older adults. This would mean that the demand for packaging material for pharmaceutical purposes is likely to rise as people with chronic disorders will require frequent administration or consumption of different drugs. In consequence, the pharmaceutical packaging market growth is set to get boosted during the forecast period as the risk factors associated with these conditions are also increasing in tandem.
The global Pharmaceutical Packaging Market report contains market revenue, market share, and production of the service providers is also mentioned with accurate data. Moreover, the global market report majorly focuses on the current developments, new possibilities, advancements, as well as dormant traps. Furthermore, the market report offers a complete analysis of the current situation and the advancement possibilities of the market across the globe.
This report analyses substantial key components such as production, capacity, revenue, price, gross margin, sales revenue, sales volume, growth rate, consumption, import, export, technological developments, supply, and future growth strategies.
Estimates released by the Population Division of the UN Department of Economic and Social Affairs (DESA) indicate that the number of persons at or above 60-years of age will reach 2.1 billion by 2050. Moreover, by the end of this decade itself older persons will outnumber children under the age of 10. Pharmaceutical packaging products are likely to experience high demand in this scenario as the uptake of drugs and their delivery mechanisms will inevitably spike as larger number of people get older at a faster rate. Moreover, novel packaging solutions such as prefilled inhalers and syringes can enable older persons to self-administer the drugs, eliminating the need to visit a hospital or clinic.
Gain More Insights into the Pharmaceutical Packaging Market Research Report https://www.fortunebusinessinsights.com/pharmaceutical-packaging-market-102860
List of Key Players Profiled in the Pharmaceutical Packaging Market Research Report:
- Gaplast Gmbh (Germany)
- CCL Industries Inc. (Canada)
- ALPLA-Werke Alwin Lehner GmbH & Co KG (Austria)
- SABIC (Saudi Arabia)
- NIPRO (Japan)
- AptarGroup, Inc. (US)
- West Pharmaceutical Services, Inc. (US)
- Schott AG (Germany)
- Nelipak Healthcare (Canada)
- Gerresheimer AG (Germany)
- Frank Noe Egypt Ltd (Egypt)
- Constantia Flexibles (Austria)
- Lonza Group AG (Switzerland)
- Carcano Antonio S.p.A. (Italy)
- Berry Global, Inc. (US)
- WestRock (US)
- Becton Dickinson & Company (US)
- Pharma Packaging Solutions (US)
- Origin Pharma Packaging (UK)
- Amcor Plc (Switzerland)
North America to Lead the Pack; Europe to Follow Closely
With a market size of USD 26.89 billion in 2019, North America is well-poised to dominate this market share in the forthcoming years. The major reasons for the market growth in this region include high healthcare spending and robust health infrastructure along with strong support to medical research in the region. Europe, the second-largest region in this market, will be driven by the escalating demand for pharmaceutical products such as vials and syringes to contain the spread of infectious diseases, including the on-going COVID-19 pandemic. The market in Asia-Pacific is expected to enjoy lucrative opportunities owing to increasing prevalence of chronic diseases and massive investments in R&D by regional pharmaceutical companies.